Contents

Pages

Foreword 11
Introduction 13
Discovery of the Sleep–Wake system 17
Twenty–four hours of Sleep–Wake system functioning 18
Therapeutic applications of this discovery 23

And for more information - FMI

FMI 1: History of the discovery of the Sleep–Wake system 29
FMI 2: The pineal gland and the photoneuroendocrine system 33
FMI 3: Development of a method for assaying melatonin in biological fluids 37
FMI 4: The circumstances of my discovery of the sleep hormone 38
FMI 5: Pharmacokinetic study of melatonin in humans 40
FMI 6: Kinetics of pineal secretion of melatonin in humans 43
FMI 7: N–acetyltransferase (NAT) enzyme activity in the pineal gland during the nychthemeron 54
FMI 8: Demonstration of acetylation of indolamines and indolamides by N–acetyltransferases (NATs) of the pineal gland 56
FMI 9: Pharmacokinetic studies of Valentonin and 6-methoxy-harmalan in dogs after intravenous bolus administration of a combination of the two hormones 63
FMI 10: Sleep 74
FMI 11: Hypnotic, «prosoporific», activity of Valentonin and valentonergics 81
FMI 12: Other pharmacological properties of Valentonin and valentonergics 95
FMI 13: Pharmacological properties of 6–methoxy-harmalan, the waking and cognition hormone 97
FMI 14: Modes of action of Valentonin and of 6-methoxy-harmalan 101
FMI 15: 2–Oxo–melatonin, produced by the reduction of free radicals by melatonin 113

Pages

FMI 16: Medications that cause drowsiness 118
FMI 17: The so–called "hypnotic" medicines currently available on the market? 121
FMI 18: What "prosoporific" medications are currently available on the market? 124
FMI 19: The saga of serotonin. Origin and role in the Sleep-Wake system 125
FMI 20: Plasma melatonin level, in the middle of the night, is a measure of the state of the Sleep–Wake system 135
FMI 21: Sleep–Wake system dysfunctions in sleep disorders 137
FMI 22: Mechanisms of depression 139
FMI 23: Sleep–Wake system dysfunctions in Parkinson's disease 143
FMI 24: Sleep–Wake system dysfunctions in Alzheimer's disease 151
FMI 25: Sleep–Wake system dysfunctions in psychotic states 160
FMI 26: Proposed treatments for neurological disorders with Sleep–Wake system hormones 166
FMI 27: Origin of current psychotropic medications From "lucky find" to "lucky find" 174
FMI 28: Interactions between Valentonin (and valentonergics) and compounds with benzodiazepine activity (benzodiazepines and related Zolpidem–type compounds) 180
FMI 29: The harm caused by benzodiazepines and related medications: explanations 186
FMI 30: Structure-activity relationships 191
FMI 31: The medications used in the potential market for Valentonin and 6–methoxy-harmalan 203
FMI 32: List of patents concerning Valentonin and its 569 new synthetic substitutes as valentonergics 204
FMI 33: Other prospective therapeutic applications of the discovery of the Sleep–Wake system 207